Advertisement
Advertisement

CMMB

CMMB logo

Chemomab Therapeutics Ltd. - ADR

1.55
USD
Sponsored
+0.05
+3.33%
Jun 24, 14:52 UTC -4
Closed
exchange

Pre-Market

1.54

-0.01
-0.32%

CMMB Earnings Reports

Positive Surprise Ratio

CMMB beat 4 of 22 last estimates.

18%

Next Report

Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.15
Implied change from Q1 26 (Revenue/ EPS)
--
/
-37.50%
Implied change from Q2 25 (Revenue/ EPS)
--
/
--

Chemomab Therapeutics Ltd. - ADR earnings per share and revenue

On May 14, 2026, CMMB reported earnings of -0.24 USD per share (EPS) for Q1 26, missing the estimate of -0.15 USD, resulting in a -51.80% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.30% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.15 USD, with revenue projected to reach -- USD, implying an decrease of -37.50% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Grace Therapeutics, Inc. Common Stock
Report Date
Jun 18, 2026 For Q4 26
Estimate
-$0.23
Actual
-$0.06
Surprise
+74.42%
FAQ
For Q1 2026, Chemomab Therapeutics Ltd. - ADR reported EPS of -$0.24, missing estimates by -51.8%, and revenue of $0.00, 0% as expectations.
The stock price moved down -2.3%, changed from $1.74 before the earnings release to $1.70 the day after.
The next earning report is scheduled for Aug 12, 2026.
Based on 3 analysts, Chemomab Therapeutics Ltd. - ADR is expected to report EPS of -$0.15 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement